Navigation Links
Frost & Sullivan: Launch of New Classes of Oral Antidiabetic Drugs by 2014 will Uplift Prospects for the European Diabetes Therapeutics Market

LONDON, June 25, 2012 /PRNewswire/ -- The alarming prevalence rate of diabetes and its significant growth over the last year has encouraged market participants in the pharmaceuticals industry to venture into the burgeoning diabetics therapeutics segment. With a slew of effective formulations in the pipeline, competition in the market will be turned up a few notches.

New analysis from Frost & Sullivan (, European Diabetes Therapeutics Market, finds that the market earned revenues of approximately $8.60 billion in 2010 and estimates this to reach approximately $13.97 billion in 2017 at a compound annual growth rate (CAGR) of 7.2 per cent from 2010-2017.

"In 2010, the incidence of diabetes was highest in Germany, with approximately 7.4 million patients, followed by France, Italy and Spain," says Frost & Sullivan Research Analyst K. Srinivas Sashidhar. "According to International Diabetes Federation (IDF) data, the prevalence is going to accelerate by 2030 and is estimated to increase in small regions such as the Benelux and Scandinavia."

The insulin market is dominated by modern insulins and analogues. Long-acting insulins are expected to have a large market in the future. New therapeutic classes of drugs are expected to be a major contributor to the OAD segment.

The expense for diabetes treatment has become a global burden, especially for the middle- and low-income groups. Participants in this space are battling pricing pressures; however, high levels of competition, improved therapies, and the introduction of biosimilars will help deal with this issue.

Major concerns surrounding drug safety and side effects have created cause for concern among participants. This factor will have an impact on the global market in the near future, considering the need for compliance with strict European Medicines Agency and Food and Drug Administration (FDA) guidelines. These issues have alarmed medicines agencies to have strict control over efficacy and safety data. As new types of products emerge in the market, safety issues are bound to have a high impact in the future.

To ensure market progression, it is vital to build awareness on disease management. Participants need access to an interdisciplinary healthcare team that must be alert to new innovations to help develop treatment plans. It is also essential to drive home the importance of diet and exercise to patients.

"New kinds of therapeutic classes, GLP-1s, and new combination therapies will take market prospects forward," says Sashidhar. "Metformin will continue to be a strong competing product in Europe."

If you are interested in more information on this study, please send an e-mail to Janique Morvan, Corporate Communications, at, with your full contact details.

European Diabetes Therapeutics Market is part of the Pharmaceuticals & Biotechnology Growth Partnership Service program, which also includes research in the following markets: European Biosimilars Market, Stem Cell Therapeutics Markets in Europe, Generics Pharmaceutical Markets - A Global Analysis, Strategic Analysis of the European Prefillable Syringes Markets, and European Pharmaceuticals and Biotech Contract Manufacturing Markets. All research services included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants.

About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.

Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

  • The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
  • The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Contact Us:     Start the discussion

Join Us:           Join our community

Subscribe:        Newsletter on "the next big thing"

Register:          Gain access to visionary innovation

European Diabetes Therapeutics Market

Janique Morvan
Corporate Communications – Europe
P: +33 (0)1 42 81 20 37
M: +33 (0)6 79 22 41 42

SOURCE Frost & Sullivan
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Frost & Sullivan to Host Complimentary Web Conference: Concerns and Solutions for the Anaesthesia Equipment and Associated Peripherals Market
2. Electronic Medical Records Progress from an Enterprise-Centric Solution to a Customer-Specific Application, Finds Frost & Sullivan
3. Frost & Sullivan: Expanding Sample Prep Market Supports Growth Trends in Molecular Diagnostics Markets
4. Frost & Sullivan: Developing Integration Capabilities Presents a Real Opportunity for Vendors in the European CIS Market
5. MicroRNA Research to Trigger Tremendous Growth in Related Tools Market, Says Frost & Sullivan
6. Frost & Sullivan Recognizes Labcyte for its Commitment to Innovation and Addressing Unmet Needs in the Liquid Handling Market
7. Heightened Awareness, Coupled with Expanding Patient Pool, Stimulates Sleep Apnea Diagnostics and Sleep Services Market, Says Frost & Sullivan
8. Frost & Sullivan Research Preview: Top 20 Telehealth Markets
9. European Thrombosis Therapeutics Market is Experiencing an Urgent Need for Enhanced Products, Says Frost & Sullivan
10. Frost & Sullivan: High Uptake of New Drug Therapies and Aging Population Expansion Keep the U.S. Retinal Therapeutics Market Buoyant
11. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
Post Your Comments:
(Date:6/24/2016)... June 24, 2016  Collagen Matrix, Inc., ("Collagen ... and manufacturing of collagen and mineral based medical ... that Bill Messer has joined the ... further leverage the growing portfolio of oral surgery, ... Bill joins the Collagen Matrix executive team ...
(Date:6/24/2016)... DUBLIN , June 24, 2016 ... and Markets has announced the addition of the ... their offering. ... products and provides an updated review, including its applications ... covering the total market, which includes three main industries: ...
(Date:6/24/2016)... BEIJING , June 24, 2016 Dehaier ... or the "Company"), which develops, markets and sells medical ... China , signed a strategic cooperation agreement with ... as "Hongyuan Supply Chain") on June 20, 2016, to ... Under the strategic cooperation agreement, Dehaier will leverage Hongyuan ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal trainer ... through a fitness app. The fitness app plans to fix the two major problems leading ... a one size fits all type program , They don’t eliminate all the ...
(Date:6/25/2016)... ... , ... Austin residents seeking Mohs surgery services, can now turn to Dr. ... Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to include ... in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn ...
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... ... the United States, named Dr. Sesan Ogunleye, as the Medical Director of its new ... the facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, ...
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health and ... their exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards took ... the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to receive ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may suffer ... unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To avoid ... healthy coping following a traumatic event. , Trauma sufferers tend to feel a range ...
Breaking Medicine News(10 mins):